Merck & Co. stock trades 0.46 percent above Xetra close
Published on 10/24/2026 at 10:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSClinical updates and trading dates
- Merck and Moderna reported a 42 percent reduction in recurrence or death risk on October 23, 2026.
- Merck & Co. stock trades in weekend trading at EUR 129.81 at 10:33 a.m. CEST on October 24, 2026, 0.46 percent above the Xetra close of October 23, 2026.
- The next Xetra session is scheduled for October 26, 2026.
Merck & Co. and Moderna reported detailed results from their Phase 3 INTerpath-001 trial on October 23, 2026. The companies said intismeran autogene combined with KEYTRUDA reduced the risk of recurrence or death by 42 percent compared with KEYTRUDA alone in patients with completely resected stage IIB to IV melanoma. The results were announced in a release distributed through Business Wire and published by BioSpace.
At 10:33 a.m. CEST on October 24, 2026, Merck & Co. stock traded in weekend trading at Lang & Schwarz at EUR 129.81. That was EUR 0.59, or 0.46 percent, above the Xetra close of October 23, 2026, at EUR 129.22. The further course of weekend trading at Lang & Schwarz until 1:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Merck & Co. stock.
In a separate announcement dated October 21, 2026, Merck said the European Commission approved KEYTRUDA plus Padcev as perioperative treatment for adults with resectable muscle-invasive bladder cancer. Merck said the approval applies regardless of cisplatin eligibility and covers all 27 European Union member states, Iceland, Liechtenstein and Norway. The company said the approval was based on Phase 3 KEYNOTE-B15 results, which showed a 47 percent reduction in the risk of event-free survival events among cisplatin-eligible patients. The announcement is available from Merck.
Market context: Market report S&P 500.
The week in figures
Merck & Co. stock was at EUR 129.81 in weekend trading at Lang & Schwarz at 10:33 a.m. CEST on October 24, 2026. The price stood 0.46 percent above the Xetra close of October 23, 2026, at EUR 129.22.
Chronology of the week
On October 21, 2026, Merck announced the European Commission approval of KEYTRUDA plus Padcev for perioperative treatment of resectable muscle-invasive bladder cancer. The company cited a 47 percent reduction in the risk of event-free survival events in the relevant Phase 3 trial. On October 23, 2026, Merck and Moderna reported INTerpath-001 results showing a 42 percent reduction in the risk of recurrence or death.
Dates of the coming week
Merck and Moderna’s INTerpath-001 results are scheduled for presentation during the 2026 European Society for Medical Oncology congress, and Merck’s next Xetra session is October 26, 2026.
